The US-Israeli Karyopharm Company has received approval from the FDA fpr a cance drug

The US-Israeli Karyopharm Company has received approval from the US Food and Drug Administration (FDA) for the marketing of the drug XPOVIO. The company's stock is up about 5% in Wall Street trading.
XPOVIO is the only oral oral (oral ingestion) drug for large B cell lymphoma (DLBCL), and is given to DLBCL patients whose disease has changed after at least two previous treatments or whose disease has developed from follicular lymphoma, characterized by seizure activity.
XPOVIO has now received marketing authorization to treat DLBCL blood cancer as a single treatment, and less than a year ago, the company received FDA approval for a myeloma blood cancer drug for patients who recovered after four different treatments.
CryoPharm received the current approval under an accelerated approval program - designed to quickly authorize cure for serious illnesses with no available treatment options - and based on the response rate to treatment. Regular approval for marketing the drug for this delineation is contingent upon the confirmation of the findings, and demonstration of clinical benefit in a validation trial.
CryoPharm received the approval after submitting the results of a clinical trial involving 134 participants, all DLBCL patients, in US and foreign hospitals. Experiment participants received 60 mg XPOVIO twice a week.
The cryoparam experiment achieved its primary goal of a total response rate of 29% at the end of the experiment, including 18 complete responses - i.e., full healing (13%), and 21 partial responses - improving the condition of the tumor (16%). One of the secondary goals of the trial was to test the overall response duration in all patients responding to XPOVIO. Approximately 56% of patients responding to the drug maintained response after three months, 38% maintained response after six months, and 15% after 12 months. The company plans to apply for the drug to the European Medicines Agency in 2021.